Coya Therapeutics

• Early-stage opportunity to contribute to a novel cell therapy modality (ex-vivo Treg modification) with potential to address unmet needs in ALS, a devastating neurodegenerative disease
• Ground-floor position at a pre-revenue biotech where individual contributions directly shape company trajectory and scientific direction
• Focused pipeline allows deep expertise building in a specific therapeutic approach with potential to establish a differentiated market position

Generated by Claude from Coya Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.